Novel ultraviolet-dermoscopy: Early diagnosis and activity evaluation of vitiligo.

BACKGROUND/OBJECTIVE: Polarized dermoscopy, Wood's lamp, and reflectance confocal microscopy were currently commonly used auxiliary technology in vitiligo clinic diagnosis. To improve the efficiency and accuracy of different periods of lesions of vitiligo, we used a novel ultraviolet (UV)-dermoscopy (Model CH-UVDS30, Ultraviolet wavelength range of 360<390nm, Chuanghong Science and Technology Company, China) in clinical observation. MATERIALS AND METHODS: Three cases of different periods of vitiligo patients were included in this study. Polarised dermoscopy and novel UV-dermoscopy (UV wavelength range of 360 nm < λ < 390 nm) were performed at 20 × magnification in polarized and UV modes. Characteristic manifestations of different periods of vitiligo lesions were captured and compared. RESULTS: The depigmented and pigmented junctional zone and perifollicular pigmentation areas could be easier and simultaneously identified via UV-dermoscopy. In a progressive vitiligo patient (woman, 42 years old, face) enhanced perifollicular pigmentation and blurred border were clearly observed. In a stable vitiligo patient (man, 27 years old, right foot) sharply demarcated border and perifollicular depigmentation could be found. In a re-pigmenting vitiligo patient (woman, 41 years old, neck) telangiectasias and pigmentation reservoirs were observed. CONCLUSION: Novel UV-dermoscopy, as a miniature and portable device, might help early diagnosis, active/progress judgment, and treatment effect evaluation of vitiligo in the clinic.

Cyclin-dependent kinase 15 upregulation is correlated with poor prognosis for patients with breast cancer.

OBJECTIVE: To investigate the clinical significance of cyclin-dependent kinase (CDK) 15 in breast cancer. METHODS: This prospective observational study enrolled 154 patients with breast cancer. Tumor tissues and paired paracancerous normal tissues were collected. Additionally, 85 samples of benign breast lesions were obtained from patients with mammary gland hyperplasia. Patient characteristics were recorded, and CDK15, human epidermal growth factor receptor (HER)2, estrogen receptor, progesterone receptor, and Ki67 immunohistochemical expression were determined. RESULTS: The rate of strong CDK15 expression was 63.6% (98/154) in breast cancer tissues, which was remarkably higher than that in benign breast lesions (34.1%, 29/85). Similarly, the ratio of strong CDK15 expression was markedly higher in tumor tissues (63.6%, 98/15) than in paracancerous normal tissues (27.3%, 42/154). Pearson's analysis showed that the CDK15 expression score was positively correlated with HER2 and Ki67. Patients with high CDK15 expression showed markedly higher ratios of TNM stage III to IV, lymph node metastasis, and increased tumor diameters but a significantly lower rate of ductal carcinoma in situ. The median survival time of these patients was significantly shorter. Kaplan-Meier curve analysis showed that low CDK15 expression predicted longer survival times. CONCLUSION: Upregulated CDK15 predicted poor clinical outcomes in breast cancer.